The U.S. stock market extended its rally into early 2025, following a strong performance in 2024. Despite concerns over trade policies and inflation, investors remained optimistic, driven by solid ...
MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell and gene therapies. Their core ExPERT ATx, sTX, GTx, and VLx tools use ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback